Dr. Reddy's to acquire generic injectables portfolio
Dr. Reddy’s is expanding its generics portfolio. The company announced that it has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications in the United States, including more than 30 generic injectable drugs.
These products will require to be technology transferred and could be launched within the next one to two years, the company said.
The products had a market value of roughly $645 million for the year ending December 2018, according to IQVIA data.
“The acquisition is in line with our stated strategy to significantly enhance our portfolio in our chosen growth markets. This transaction will help augment our injectables product portfolio in the U.S. market and globally.” Erez Israeli, Dr. Reddy’s COO said.
These products will require to be technology transferred and could be launched within the next one to two years, the company said.
The products had a market value of roughly $645 million for the year ending December 2018, according to IQVIA data.
“The acquisition is in line with our stated strategy to significantly enhance our portfolio in our chosen growth markets. This transaction will help augment our injectables product portfolio in the U.S. market and globally.” Erez Israeli, Dr. Reddy’s COO said.